Valuation
26% of the score
100median 53
Ironwood Pharmaceuticals, Inc. is valued at 2.4x its operating profit, including debt: cheap enough for full points.
60x
50x
35x
25x
18x
12x
8x
2.4x
Full points at 8x or less, none from 60xfull points
IRWDIronwood Pharmaceuticals, Inc.
$3.46+120% 1Y
$3.46
$1.5052 weeks$5.39
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 48 out of 100, Average
Average. Ironwood Pharmaceuticals, Inc. scores higher than 42% of the 2,231 companies Ryufin scores.
Carried by valuation and capital allocation, held back by return on capital and return on new capital.
Healthcare median 19 · all companies 55
How the score has moved
At each fiscal year end, from the reports and price of the time65
76
75
27
53
48
20202021202220232024today
The biggest move was down 48 points from 2022 to 2023, mostly valuation.
Return on capital
18% of the score
0median 24
Over 7 years the business earned -11% a year after tax on the capital it uses.
2%
8%
15%
25%
-11%
None at 2% or less, full points from 25%full points
7 years agolatest 79%
Return on new capital
16% of the score
0median 33
No operating profit over the period, so nothing was earned to reinvest.
Capital allocation
14% of the score
73median 63
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 0.3% a year over 5 years: new shares
595%
-3%
0.3%
0 pointsfull points
Assets against salesAssets grew -6.6% a year, sales -5.3%
9512%
-2%
-1.3%
0 pointsfull points
Cycle position
12% of the score
12median 63
Today's operating margin of 60% is 1.75x its normal 34%: near a peak, where margins tend to fall back. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
2x
1.5x
1x
0.7x
1.8x
A trough earns points, a peak costs themfull points
10 years agonow 60%
Balance sheet
8% of the score
54median 50
What the debt weighs against the profit that has to carry it.
Interest coverOperating profit covers interest 7x
541.5x
12x
7.2x
0 pointsfull points
Earnings quality
6% of the score
100median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
AccrualsCash ran ahead of profit by 27.6% of assets
1008%
0%
-8%
-28%
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Drug Manufacturers, Specialty & Generic
Ranks #17 of 39 by RyuScore